Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, …, Cullis PR (2019) The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol 14(12), 1084–1087

Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, …, Beigel JH (2020) Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 383(25), 2427–2438

AP üyesinden öneri: Euro banknotları üzerinde Özlem Türeci ve Uğur Şahin’in de fotoğrafları olsun - BBC News Türkçe. (n.d.). Retrieved November 16, 2022, from https://www.bbc.com/turkce/haberler-dunya-59857624

Aşının fiyatı belli oldu. (n.d.). Retrieved November 16, 2022, from https://www.inbusiness.com.tr/in-business/2020/11/13/asinin-fiyati-belli-oldu

Baden LR, Hana M, Sahly El, Essink Brandon, Kotloff Karen, Frey Sharon, Novak Rick, Diemert David, Spector Stephen A, Nadine Rouphael C, Creech Buddy, McGettigan John, Khetan Shishir et al (2021) Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 384:403–416

Article  CAS  PubMed  Google Scholar 

BioNTech | Fighting the global pandemic with Project Lightspeed (2020). Retrieved November 16, 2022, n.d. from https://www.biontech.com/int/en/home/covid-19/project-lightspeed.html

Covid-19 aşısının arkasındaki iki isim: Türkiye kökenli Uğur Şahin ve Özlem Türeci (2020) Euronews. https://tr.euronews.com/2020/11/10/covid-19-as-s-n-n-arkas-ndaki-iki-isim-turkiye-kokenli-ugur-sahin-ve-ozlem-tureci

Evers MJ, Kulkarni JA, van der Meel R, Cullis PR, Vader P, Schiffelers RM (2018) State-of-the-art design and rapid-mixing production techniques of lipid nanoparticles for nucleic acid delivery. Small Methods 2(9):1700375

Article  Google Scholar 

FDA Approves First COVID-19 Vaccine. (2021, August 23). FDA approves first COVID-19 vaccine | FDA. Retrieved November 14, 2022, from https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine

Ganymed AK (n.d.) web.archive.org . Retrieved November 16, 2022, from https://web.archive.org/web/20200711233156/https://transkript.de/news/astellas-kauft-ganymed.html

Gelles D (2020) The husband-and-wife team behind the leading vaccine to solve covid-19. The New York Times. https://www.nytimes.com/2020/11/10/business/biontech-covid-vaccine.html

Hadas Y, Sultana N, Youssef E, Sharkar MTK, Kaur K, Chepurko E, Zangi L (2019) Optimizing modified mRNA in vitro synthesis protocol for heart gene therapy. Molec Ther-Methods Clin Dev 14:300–305

Article  CAS  Google Scholar 

Hayashi CT, Cao Y, Clark LC, et al. (2022) mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum. NPJ Vaccines 7(1). https://doi.org/10.1038/s41541-022-00577-8

Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, … , Sahin U (2006) Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood, 108(13), 4009–4017.

Home - Johns Hopkins Coronavirus Resource Center. (n.d.). Johns Hopkins Coronavirus Resource Center. Retrieved November 13, 2022, from https://coronavirus.jhu.edu/

Hu B, Guo H, Zhou P, Shi ZL (2021) Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 19(3):141–154

Article  CAS  PubMed  Google Scholar 

Janowski M, Andrzejewska A (2022) The legacy of mRNA engineering–a line-up of pioneers for the Nobel Prize. Molec Ther-Nucleic Acids

Jurga S, Barciszewski J (2022) Messenger RNA therapeutics. Springer Nature

Karikó K, Buckstein M, Ni H, Weissman D (2005) Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23(2):165–175

Article  PubMed  Google Scholar 

Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D (2008) Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16(11):1833–1840

Article  PubMed  Google Scholar 

Klusmann S, Schulz T (2021) a-41ce9633–5b27–4b9c-b1d7–1bf94c29aa43. DER SPIEGEL, Hamburg, Germany. Retrieved November 18, 2022, from https://www.spiegel.de/international/world/biontech-founders-tuereci-and-sahin-on-the-battle-against-covid-19-to-see-people-finally-benefitting-from-our-work-is-really-moving-a-41ce9633-5b27-4b9c-b1d7-1bf94c29aa43

Koski GK, Karikó K, Xu S, Weissman D, Cohen PA, Czerniecki BJ (2004) Cutting edge: innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells. J Immunol 172(7):3989–3993

Article  CAS  PubMed  Google Scholar 

Krammer F (2020) SARS-CoV-2 vaccines in development. Nature 586(7830):516–527

Article  CAS  PubMed  Google Scholar 

Kuhn AN, Diken M, Kreiter S, Selmi A, Kowalska J, Jemielity J, …, Sahin U (2010) Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther 17(8), 961–971

Kumar A, Blum J, Le TT, Havelange N, Magini D, Yoon IK (2022) The mRNA vaccine development landscape for infectious diseases. Nat Rev Drug Discov 21(5):333–334

Article  CAS  PubMed  Google Scholar 

Moderna and Merck announce mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA(R) (pembrolizumab), met primary efficacy endpoint in phase 2b KEYNOTE-942 trial. (n.d.). Retrieved 1 October 2023, from https://investors.modernatx.com/news/news-details/2022/Moderna-and-Merck-Announce-mRNA-4157V940-an-Investigational-Personalized-mRNA-Cancer-Vaccine-in-Combination-with-KEYTRUDAR-pembrolizumab-Met-Primary-Efficacy-Endpoint-in-Phase-2b-KEYNOTE-942-Trial/default.aspx

Moderna announces clinical progress from its industry-leading mRNA vaccine franchise and continues investments to accelerate (2021) Bloomberg.com. Retrieved 1 October 2023, from https://www.bloomberg.com/press-releases/2021-04-14/moderna-announces-clinical-progress-from-its-industry-leading-mrna-vaccine-franchise-and-continues-investments-to-accelerate

Moderna announces positive interim phase 1 data for mRNA flu vaccine and provides program update. (n.d.). Retrieved 1 October 2023, from https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-Positive-Interim-Phase-1-Data-for-mRNA-Flu-Vaccine-and-Provides-Program-Update/default.aspx

Ni H, Capodici J, Cannon G, Communi D, Boeynaems JM, Karikó K, Weissman D (2002) Extracellular mRNA induces dendritic cell activation by stimulating tumor necrosis factor-α secretion and signaling through a nucleotide receptor∗. J Biol Chem 277(15):12689–12696

Article  CAS  PubMed  Google Scholar 

Oltermann P (2020) Uğur Şahin and Özlem Türeci: German “dream team” behind vaccine. Retrieved November 16, 2022, from http://www.theguardian.com/world/2020/nov/10/ugur-sahin-and-ozlem-tureci-german-dream-team-behind-vaccine

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study | Pfizer. (n.d.). Retrieved 1 October 2023, from https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Gruber WC (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England J Med 383(27):2603–2615

Article  CAS  Google Scholar 

Sahin U (n.d.) www.sfb1399.de. Retrieved November 16, 2022, from https://web.archive.org/web/20200711233156/https://transkript.de/news/astellas-kauft-ganymed.html

Şahin U (n.d.) leopoldina.org. Retrieved November 16, 2022, from https://www.leopoldina.org/fileadmin/redaktion/Mitglieder/CV_%C5%9Eahin_U%C4%9Fur_EN.pdf

Migration und Qualifikation (n.d.) DER STANDARD. https://www.derstandard.at/story/2000122601040/migration-und-qualifikation

Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D (2016) mRNA vaccine delivery using lipid nanoparticles. Ther Deliv 7(5):319–334

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rozman M, Korać P, Jambrosic K, Židovec LS (2022) Progress in prophylactic and therapeutic EBV vaccine development based on molecular characteristics of EBV target antigens. Pathogens 11(8):864. https://doi.org/10.3390/pathogens11080864

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spotlight: The Turkish-German “dream team” couple behind Pfizer’s COVID-19 vaccine. (2020, November 9). Daily Sabah. https://www.dailysabah.com/life/science/spotlight-the-turkish-german-dream-team-couple-behind-pfizers-covid-19-vaccine

Steinman RM, Witmer MD (1978) Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci 75(10):5132–5136

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stepinski J, Waddell C, Stolarski R, Darzynkiewicz E, Rhoads RE (2001) Synthesis and properties of mRNAs containing the novel “anti-reverse” cap analogs 7-methyl (3′-O-methyl) GpppG and 7-methyl (3′-deoxy) GpppG. RNA 7(10):1486–1495

CAS  PubMed  PubMed Central  Google Scholar 

Sun L, Shen L, Fan J, Gu F, Hu M, An Y, …, Bi J (2020) Clinical features of patients with coronavirus disease 2019 from a designated hospital in Beijing, China. J Med Virol 92(10):2055–2066

Wrede I (2020) German researchers advance coronavirus vaccine. dw.com. Retrieved 14 November 2022, from https://www.dw.com/en/german-researchers-advance-coronavirus-vaccine/a-55549895

Yu T (2021) How Scientists Drew Weissman (MED’87, GRS’87) and Katalin Karikó Developed the Revolutionary mRNA Technology inside COVID Vaccines. Boston University. Retrieved 16 November 2022, from https://www.bu.edu/articles/2021/how-drew-weissman-and-katalin-kariko-developed-mrna-technology-inside-covid-vaccines/